{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:08:26Z","timestamp":1766167706247,"version":"3.48.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03481-x","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T19:00:58Z","timestamp":1743706858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"45","author":[{"given":"Xinli","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"3481_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OPTH.S385827","volume":"17","author":"P Sen","year":"2023","unstructured":"Sen P, Manayath G, Shroff D et al (2023) Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol 17:53\u201370","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3481_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/APO.0000000000000573","volume":"12","author":"P Ruamviboonsuk","year":"2023","unstructured":"Ruamviboonsuk P, Lai TYY, Chen SJ et al (2023) Polypoidal choroidal vasculopathy: updates on risk factors, diagnosis, and treatments. Asia Pac J Ophthalmol 12(2):184\u2013195","journal-title":"Asia Pac J Ophthalmol"},{"key":"3481_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK et al (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107\u2013139","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"3481_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/01.APO.0000656992.00746.48","volume":"9","author":"V Chaikitmongkol","year":"2020","unstructured":"Chaikitmongkol V, Cheung CMG, Koizumi H et al (2020) Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment. Asia Pac J Ophthalmol 9(3):260\u2013268","journal-title":"Asia Pac J Ophthalmol"},{"issue":"2","key":"3481_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jfma.2019.04.012","volume":"119","author":"LJ Chen","year":"2020","unstructured":"Chen LJ, Cheng CK, Yeung L et al (2020) Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan. J Formos Med Assoc 119(2):569\u2013576","journal-title":"J Formos Med Assoc"},{"key":"3481_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M et al (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182\u2013199","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"3481_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.survophthal.2023.04.002","volume":"68","author":"A Hatamnejad","year":"2023","unstructured":"Hatamnejad A, Patil NS, Mihalache A et al (2023) Efficacy and safety of anti-vascular endothelial growth agents for the treatment of polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Surv Ophthalmol 68(5):920\u2013928","journal-title":"Surv Ophthalmol"},{"issue":"3\u20134","key":"3481_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000533529","volume":"246","author":"A Mihalache","year":"2023","unstructured":"Mihalache A, Hatamnejad A, Patil NS et al (2023) Anti-vascular endothelial growth factor therapy regimens for polypoidal choroidal vasculopathy: a systematic review. Ophthalmologica 246(3\u20134):245\u2013254","journal-title":"Ophthalmologica"},{"issue":"7","key":"3481_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y et al (2018) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 136(7):786\u2013793","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"3481_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00417-020-04988-y","volume":"259","author":"LH Ye","year":"2021","unstructured":"Ye LH, Cai Y, Shi X et al (2021) One-year results of intravitreal conbercept in treatment-na\u00efve subjects with polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 259(6):1455\u20131462","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"3481_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y et al (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740\u20131747","journal-title":"Ophthalmology"},{"issue":"5","key":"3481_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/IAE.0000000000000875","volume":"36","author":"J Qu","year":"2016","unstructured":"Qu J, Cheng Y, Li X et al (2016) Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the aurora study. Retina 36(5):926\u2013937","journal-title":"Retina"},{"issue":"5","key":"3481_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","volume":"39","author":"Z Huang","year":"2019","unstructured":"Huang Z, Ding Q, Yan M et al (2019) Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina 39(5):889\u2013895","journal-title":"Retina"},{"issue":"1","key":"3481_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148(1):43-58.e1","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"3481_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464","journal-title":"Retina"},{"key":"3481_CR16","doi-asserted-by":"publisher","first-page":"4924053","DOI":"10.1155\/2020\/4924053","volume":"2020","author":"Y Wang","year":"2020","unstructured":"Wang Y, Shen M, Cheng J et al (2020) The efficacy of conbercept in polypoidal choroidal vasculopathy: a systematic review. J Ophthalmol 2020:4924053","journal-title":"J Ophthalmol"},{"issue":"6","key":"3481_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","volume":"126","author":"PJ Kertes","year":"2019","unstructured":"Kertes PJ, Galic IJ, Greve M et al (2019) Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology 126(6):841\u2013848","journal-title":"Ophthalmology"},{"issue":"9","key":"3481_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","volume":"31","author":"SR Rufai","year":"2017","unstructured":"Rufai SR, Almuhtaseb H, Paul RM et al (2017) A systematic review to assess the \u2018treat-and-extend\u2019 dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye 31(9):1337\u20131344","journal-title":"Eye"},{"issue":"6","key":"3481_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY et al (2021) Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina society. Asia Pac J Ophthalmol 10(6):507\u2013518","journal-title":"Asia Pac J Ophthalmol"},{"issue":"14","key":"3481_CR20","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/s41433-023-02439-6","volume":"37","author":"PAH Nichani","year":"2023","unstructured":"Nichani PAH, Popovic MM, Dhoot AS et al (2023) Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye 37(14):2855\u20132863","journal-title":"Eye"},{"issue":"1","key":"3481_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000518235","volume":"245","author":"R Silva","year":"2022","unstructured":"Silva R, Arias L, Nunes S et al (2022) Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: a randomized clinical trial. Ophthalmologica 245(1):80\u201390","journal-title":"Ophthalmologica"},{"issue":"3","key":"3481_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA et al (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther 37(3):1173\u20131187","journal-title":"Adv Ther"},{"issue":"7","key":"3481_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","volume":"106","author":"KYC Teo","year":"2022","unstructured":"Teo KYC, Jordan-Yu JM, Tan ACS et al (2022) Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. Br J Ophthalmol 106(7):987\u2013993","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"3481_CR24","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","volume":"259","author":"M Ohji","year":"2021","unstructured":"Ohji M, Okada AA, Sasaki K et al (2021) Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol 259(12):3637\u20133647","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3481_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40123-020-00312-3","volume":"9","author":"T Tamachi","year":"2020","unstructured":"Tamachi T, Kohno T, Yamamoto M et al (2020) One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmol Ther 9(4):1069\u20131082","journal-title":"Ophthalmol Ther"},{"key":"3481_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK et al (2019) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol 204:80\u201389","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3481_CR27","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s12325-022-02162-w","volume":"39","author":"AA Okada","year":"2022","unstructured":"Okada AA, Takahashi K, Ohji M et al (2022) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in the ALTAIR study: 96-week outcomes in the polypoidal choroidal vasculopathy subgroup. Adv Ther 39(6):2984\u20132998","journal-title":"Adv Ther"},{"issue":"11","key":"3481_CR28","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K et al (2017) Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 135(11):1206\u20131213","journal-title":"JAMA Ophthalmol"},{"key":"3481_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/DDDT.S158368","volume":"12","author":"Y Peng","year":"2018","unstructured":"Peng Y, Zhang X, Li M et al (2018) Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Drug Des Devel Ther 12:339\u2013345","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"3481_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12886-019-1156-4","volume":"19","author":"X Gu","year":"2019","unstructured":"Gu X, Yu X, Dai H (2019) Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy. BMC Ophthalmol 19(1):153","journal-title":"BMC Ophthalmol"},{"key":"3481_CR31","first-page":"251584141983115","volume":"11","author":"A Kumar","year":"2019","unstructured":"Kumar A, Kumawat D, Sundar MD et al (2019) Polypoidal choroidal vasculopathy: a comprehensive clinical update. Ther Adv Ophthalmol 11:2515841419831152","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"3481_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/tjo.tjo_35_18","volume":"9","author":"AH Palkar","year":"2019","unstructured":"Palkar AH, Khetan V (2019) Polypoidal choroidal vasculopathy: an update on current management and review of literature. Taiwan J Ophthalmol 9(2):72\u201392","journal-title":"Taiwan J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03481-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:01Z","timestamp":1766167441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03481-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03481-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of Harbin 242 Hospital. Written informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Research Ethics Board approved our request to publish anonymized data for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No informed consent was obtained from participants as data collected were retrospective in nature and part of the standard of care examination. This was approved by the ethics committee of Harbin 242 Hospital and adhered to the Tenet\u2019s of Helsinki for retrospective studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"139"}}